Marshall Wace North America’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-6,896
| Closed | -$663K | – | 1475 |
|
|
2020
Q3 | $663K | Buy |
+6,896
| New | +$663K | ﹤0.01% | 904 |
|
|
2020
Q2 | – | Sell |
-2,149
| Closed | -$186K | – | 1357 |
|
|
2020
Q1 | $186K | Buy |
2,149
+573
| +36% | +$49.6K | ﹤0.01% | 905 |
|
|
2019
Q4 | $169K | Sell |
1,576
-134,365
| -99% | -$14.4M | ﹤0.01% | 1000 |
|
|
2019
Q3 | $12.3M | Buy |
+135,941
| New | +$12.3M | 0.07% | 231 |
|
|
2019
Q2 | – | Sell |
-580,904
| Closed | -$51.2M | – | 1446 |
|
|
2019
Q1 | $51.2M | Buy |
580,904
+264,402
| +84% | +$23.3M | 0.36% | 82 |
|
|
2018
Q4 | $22.6M | Sell |
316,502
-158,938
| -33% | -$11.3M | 0.22% | 97 |
|
|
2018
Q3 | $58.5M | Sell |
475,440
-127,535
| -21% | -$15.7M | 0.4% | 63 |
|
|
2018
Q2 | $59.2M | Buy |
602,975
+164,189
| +37% | +$16.1M | 0.33% | 68 |
|
|
2018
Q1 | $36.4M | Sell |
438,786
-115,402
| -21% | -$9.57M | 0.18% | 132 |
|
|
2017
Q4 | $43M | Sell |
554,188
-160,280
| -22% | -$12.4M | 0.24% | 95 |
|
|
2017
Q3 | $43.6M | Buy |
714,468
+152,128
| +27% | +$9.28M | 0.28% | 84 |
|
|
2017
Q2 | $25.9M | Sell |
562,340
-249,540
| -31% | -$11.5M | 0.19% | 139 |
|
|
2017
Q1 | $34.9M | Buy |
+811,880
| New | +$34.9M | 0.28% | 104 |
|